CR8088A - DERIVADOS DE AZAINDOL COMO INHIBIDORES DEL FACTOR Xa - Google Patents

DERIVADOS DE AZAINDOL COMO INHIBIDORES DEL FACTOR Xa

Info

Publication number
CR8088A
CR8088A CR8088A CR8088A CR8088A CR 8088 A CR8088 A CR 8088A CR 8088 A CR8088 A CR 8088A CR 8088 A CR8088 A CR 8088A CR 8088 A CR8088 A CR 8088A
Authority
CR
Costa Rica
Prior art keywords
factor
compounds
situations
formula
inhibitors
Prior art date
Application number
CR8088A
Other languages
English (en)
Inventor
Marc Nazare
Volkmar Wehner
David William Will
Kurt Ritter
Matthias Urmann
Hans Matter
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of CR8088A publication Critical patent/CR8088A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a compuestos de la formula (I) en la que R0, R1, R2, R3, Q, V, G y M tienen los significados indicados en las reivindicaciones. Los compuestos de la formula (I) son compuestos farmacologicamente activos valiosos. Muestran un fuerte efecto antitrombotico y son adecuados, por ejemplo, para la terapia y profilaxis de trastornos cardiovasculares tales como enfermedades tromboembolicas o reestenosis. Son inhibidores reversibles de las enzimas de la coagulacion sanguinea factor Xa (FXa) y/o factor VIIa (FVIIa) y, en general pueden aplicarse en situaciones en las que esta presente una actividadindeseada del factor Xa y/o del factor VIIa o en situaciones para cuya curacion o prevencion se desea la inhibicion del factor Xa y/o del factor VIIa.
CR8088A 2003-05-19 2005-11-11 DERIVADOS DE AZAINDOL COMO INHIBIDORES DEL FACTOR Xa CR8088A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03011304A EP1479680A1 (en) 2003-05-19 2003-05-19 Azaindole derivatives as Factor Xa inhibitors

Publications (1)

Publication Number Publication Date
CR8088A true CR8088A (es) 2006-09-22

Family

ID=33040951

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8088A CR8088A (es) 2003-05-19 2005-11-11 DERIVADOS DE AZAINDOL COMO INHIBIDORES DEL FACTOR Xa

Country Status (24)

Country Link
EP (2) EP1479680A1 (es)
JP (1) JP4733642B2 (es)
KR (1) KR20060012636A (es)
CN (1) CN100347172C (es)
AR (1) AR045682A1 (es)
AU (1) AU2004238500B2 (es)
BR (1) BRPI0410429A (es)
CA (1) CA2526084A1 (es)
CL (1) CL2004001079A1 (es)
CR (1) CR8088A (es)
EC (1) ECSP056179A (es)
MA (1) MA27799A1 (es)
MX (1) MXPA05012156A (es)
NO (1) NO20055911L (es)
NZ (1) NZ543669A (es)
OA (1) OA13169A (es)
PE (1) PE20050554A1 (es)
RS (1) RS20050857A (es)
RU (1) RU2330853C2 (es)
TN (1) TNSN05296A1 (es)
TW (1) TW200510411A (es)
UA (1) UA86767C2 (es)
WO (1) WO2004101563A1 (es)
ZA (1) ZA200508150B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2351940T3 (es) * 2005-11-18 2011-02-14 F. Hoffmann-La Roche Ag Derivados de azaindol-2-carboxamida.
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
KR20150044895A (ko) 2012-08-17 2015-04-27 바이엘 크롭사이언스 아게 살곤충제 및 살응애제로서의 아자인돌 카르복실산 아미드 및 아자인돌 티오카르복실산 아미드
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN111834531B (zh) * 2019-04-15 2022-04-19 天津大学 一种有机半导体材料、制备方法及应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1241472B (it) 1990-07-06 1994-01-17 Olivier Linda Dispositivo elettromeccanico per la cattura continua in particolare di topi e ratti.
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
AU707653B2 (en) 1994-04-26 1999-07-15 Selectide Corporation Factor Xa inhibitors
ZA964008B (en) * 1995-06-02 1997-07-11 Akzo Nobel Nv Imidazo[1,5a]pyridine derived serine protease inhibitors
EP1040108B1 (en) * 1997-12-19 2004-02-25 Schering Aktiengesellschaft Ortho-anthranilamide derivatives as anti-coagulants
PT1042287E (pt) * 1997-12-24 2005-08-31 Aventis Pharma Gmbh Derivados de indole como inibidores do factor xa
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
JP4241970B2 (ja) * 1998-10-30 2009-03-18 中外製薬株式会社 アミド結合を有するインドール誘導体、及びモノ又はジアザインドール誘導体
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
ES2316383T3 (es) * 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
JP2001294572A (ja) * 2000-02-09 2001-10-23 Dai Ichi Seiyaku Co Ltd 新規スルホニル誘導体
US6436965B1 (en) * 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
AU2001273040A1 (en) * 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
CA2440803A1 (en) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
WO2002080853A2 (en) * 2001-04-09 2002-10-17 Bristol-Myers Squibb Company Fused heterocyclic inhibitors of factor xa
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
AU2002366801B8 (en) * 2001-12-20 2009-05-21 Osi Pharmaceuticals, Inc. Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
DE10214832A1 (de) * 2002-04-04 2003-10-16 Merck Patent Gmbh Phenylderivate 4
JP2004203791A (ja) * 2002-12-25 2004-07-22 Dai Ichi Seiyaku Co Ltd 芳香族化合物
JP2004210716A (ja) * 2002-12-27 2004-07-29 Dai Ichi Seiyaku Co Ltd ジアミド誘導体
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors

Also Published As

Publication number Publication date
KR20060012636A (ko) 2006-02-08
TW200510411A (en) 2005-03-16
OA13169A (en) 2006-12-13
RU2005139557A (ru) 2007-06-27
MA27799A1 (fr) 2006-03-01
JP4733642B2 (ja) 2011-07-27
WO2004101563A1 (en) 2004-11-25
PE20050554A1 (es) 2005-08-04
UA86767C2 (ru) 2009-05-25
AU2004238500B2 (en) 2010-07-22
AR045682A1 (es) 2005-11-09
EP1479680A1 (en) 2004-11-24
JP2006528214A (ja) 2006-12-14
CN100347172C (zh) 2007-11-07
ECSP056179A (es) 2006-08-30
EP1636226A1 (en) 2006-03-22
MXPA05012156A (es) 2006-08-18
AU2004238500A1 (en) 2004-11-25
NZ543669A (en) 2008-12-24
NO20055911L (no) 2006-02-10
CL2004001079A1 (es) 2005-04-08
ZA200508150B (en) 2007-02-28
CN1791601A (zh) 2006-06-21
HK1089175A1 (zh) 2006-11-24
TNSN05296A1 (en) 2007-07-10
BRPI0410429A (pt) 2006-06-06
CA2526084A1 (en) 2004-11-25
RU2330853C2 (ru) 2008-08-10
EP1636226B1 (en) 2014-10-15
RS20050857A (sr) 2007-11-15

Similar Documents

Publication Publication Date Title
UY28778A1 (es) Derivados de pirrol como inhibidores del factor xa
ECSP045115A (es) INDOL-2-CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
UY28325A1 (es) Nuevos derivados de indol como inhibidores del factor xa
PE20050153A1 (es) DERIVADOS DE INDAZOL COMO INHIBIDORES DEL FACTOR Xa
MX2025010920A (es) Compuestos quimicos
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
EA201001523A1 (ru) Ингибиторы матриксной металлопротеазы на основе арилсульфонамида
MX2009009623A (es) Inidol y bencimidazol amidas como inhibidores de la dehidrogenasa hidroxi-esteroide.
NO20024014D0 (no) Ny bruk av fenylheteroalkylaminderivater
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ATE331711T1 (de) Entzündungshemmende 3-arylthio-3- thiazolylalkylamine
PA8816101A1 (es) Clorotiofeno - amidas como inhibidores de los factores de coagulacion xa y trombina
GT200500026A (es) Derivados de beta-aminoacidos como inhibidores del factor xa.
CR8087A (es) DERIVADOS DE BENCIMIDAZOL COMO INHIBIDORES DEL FACTOR Xa
AR026257A1 (es) N-guanidinoalquilamidas, su preparacion, su uso y composiciones farmaceuticas que las contienen
CR8088A (es) DERIVADOS DE AZAINDOL COMO INHIBIDORES DEL FACTOR Xa
PE20050154A1 (es) DERIVADOS DE TRIAZOL COMO INHIBIDORES DEL FACTOR Xa
EP4119165A4 (en) NOVEL 3,5-DIAMINOBENZOIC ACID COMPOUND, AND PIN1 INHIBITOR AND THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES USING SAME
TW200504027A (en) Imidazole-derivatives as factor Xa inhibitors
UY28993A1 (es) Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm, procedimiento para su uso como medicamento.-
NO20061821L (no) Amidometylsubstituerte 1-(karboksyalkyl)-syklopentylkarbonylaminobenzazepin-N-eddiksyrederivater, fremgangsmate og mellomprodukter for deres fremstilling, og medikamenter som inneholder disse forbindelsene
NO20024013L (no) Ny anvendelse av fenylheteroalkylaminderivater
SV2007002534A (es) Derivados de (sulfamoil-alquil)- amida de acido heteroaril-carboxilico como inhibidores de factor xa
SV2003001524A (es) Nuevos derivados de indol como inhibidores del factor xa
UY27810A1 (es) Nuevos derivados de indol como inhibidores del factor xa.

Legal Events

Date Code Title Description
FC90 Application suspended